Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
KindredBio is focused on bringing breakthrough human products and innovative new t...
KindredBio is focused on bringing breakthrough ...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.